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Motor Symptoms as a Prodrome to Schizophrenia
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ABSTRACT
Schizophrenia occurs in 1% of the population and severely impairs those afflicted.
Thereby, it is of the utmost importance to recognize and treat the disorder as
early as possible. For the last several decades, research has attempted to elucidate
various predictive factors to aid in identifying patients at high risk of developing a
schizophrenia spectrum disorder. These factors include premorbid or prodromal
movement symptoms. The literature has identified motor aberrations beginning early
in life, in some cases even in infancy, ranging from neonatal hypotonicity to facial
and upper body dyskinesia. These motor symptoms have been demonstrated to aid
in predicting conversion to schizophrenia and carry prognostic importance for other
outcomes. We present the case of a 34-year-old male who developed abnormal motor
symptoms several years prior to the onset of psychosis. Our case builds upon the
current body of literature by demonstrating the importance of spontaneous dyskinesia
in evaluating populations at high risk for developing a schizophrenia spectrum illness,
such as individuals with a family history of psychotic illness, schizotypal personality
disorder, or other prodromal signs.
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INTRODUCTION
Schizophrenia is a devastating and costly disease,
costing sixty billion dollars per year in the United
States. With nearly 1% of the world’s population
afflicted, new techniques for identifying at-risk
individuals are critically important.1 Unfortunately,
clinical detection often occurs after the disease has
caused marked impairment. Evidence indicates
that through early identification of core prodromal
symptoms, rapid and aggressive intervention can
significantly improve prognosis.2
Outside of psychopharmacologic exposure, motoric
symptoms have been identified as a key component
of the illness. For example, Eugene Bleuler observed
irregular movements in schizophrenic patients
before the advent of modern psychopharmacologic
agents.3 Similarly, contemporary studies have
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reported spontaneous dyskinesias in medication
naïve patients.4 Motor symptoms do not appear to
be limited to the active phase schizophrenia either,
as literature supports the existence of motoric
abnormalities before the onset of psychosis, even as
early as childhood.5 Additionally, motor symptoms
have validity in predicting transition to psychotic
illness in high-risk groups (first-degree relative with
history of psychotic illness, schizotypal personality
disorder, or prodromal signs) and are correlated with
disease severity and functional outcomes.6,7
CASE REPORT
The patient was a 34-year-old male initially treated
for attention deficit hyperactivity disorder, an
unspecified depressive illness, and severe social
anxiety. Symptoms were initially managed with
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alprazolam, amphetamine-dextroamphetamine,
and doxepin, which were stopped when he moved
in with his parents and established with a new
physician after living alone during his early twenties.
Soon after, he developed facial tics including perioral
twitching, rapid eye blinking, intermittent anteroand retro torticollis, rotation of the upper torso, and
asymmetric shoulder shrugging. He also developed
severe right-sided facial pain.
He was seen by neurology between 2013 and
2014, during which head computed tomography,
magnetic resonance imaging, and angiography were
performed and found to be without abnormality.
Carbamazepine, gabapentin, and cyclobenzaprine
were started for diagnoses of blepharospasm and an
unspecified tic disorder. Later, he followed up with a
psychiatrist who added sertraline and clonazepam to
his regimen for depressive and anxious symptoms.
In 2014, the patient transferred care to local
neurology and psychiatry services. Quetiapine 25mg
was added by neurology to treat continued motor
symptoms and stopped shortly thereafter with
concern that symptoms were psychogenic. After
2016, the patient began to follow up exclusively with
psychiatry. At that time, diagnoses included major
depressive disorder, attention deficit hyperactivity
disorder, social anxiety, and panic disorders. He
was treated with duloxetine 90mg daily and
clonazepam, later changed to lorazepam 1mg three
times daily. He was also re-trialed on amphetaminedextroamphetamine for impaired concentration,
which was stopped after the patient developed
auditory hallucinations; these resolved shortly
thereafter.
In 2017, the patient’s family notified the psychiatry
clinic that he had been suffering from a recurrence
of perceptual disturbances, now with associated
paranoid ideation. Recommendations were given for
emergent evaluation in the emergency department
and psychiatric hospitalization. The patient ceased
coming to appointments until later that year when
his family called again, reporting similar symptoms.
The patient was also now experiencing command
hallucinations instructing him to harm himself,
leading to the patient fleeing his home.
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Several weeks later, the patient arrived for a
scheduled outpatient appointment. He reported
ongoing psychotic symptoms, including both
commenting and command auditory hallucinations
involving multiple voices, as well as ongoing
delusional ideation involving the FBI planting
recording devices in his home. Speech and thought
were disorganized, and previously reported motor
symptoms were appreciated on examination,
noted by the patient to have never resolved. The
patient was started on olanzapine, titrated to 15mg
daily, and lorazepam and duloxetine continued.
His diagnosis was modified to schizophrenia,
paranoid type. On subsequent visits, the patient
demonstrated significant improvement in both
perceptual and cognitive disturbances and his
motoric symptoms.
DISCUSSION
Schizophrenia commonly devastates a patient’s
ability to function. With an average age of onset in
the third decade of life, schizophrenia strikes when
an individual would otherwise be establishing
independence.8 Because diagnosis is clinical,
symptoms are often already causing marked
impairment by the time they are recognized. With
the impact of schizophrenia being so costly for
patients and the healthcare system, research has
focused on establishing reliable markers to identify
at-risk populations to allow for earlier intervention.
Prodromal movement symptoms hold diagnostic
and prognostic value and are associated with
increased risk of transitioning to psychosis and
worsened prognosis.9,10 Before the advent of
antipsychotic medications, movement disorders
were recognized as commonplace in schizophrenia
and innate to the disease.3 Now, they are mostly
viewed as iatrogenic. However, recent research has
identified motor symptoms as widely present in
high-risk patients and a critical component in their
evaluation.11,12 For example, Mittal et al. examined
the relationship between movement disorders in
adolescents with schizotypal personality disorder, a
diagnosis associated with schizophrenia. The authors
found that patients at risk for psychosis possessed
greater degrees of motor abnormality in the period
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prior to the onset of psychotic symptoms.6 Moreover,
Peralta et al. examined treatment-naïve patients
with schizophrenia and found a prevalence of motor
abnormalities in 66%, demonstrating the existence
of motor symptoms outside of antipsychotic use.12
Though we cannot rule out that our patient’s
development of motor symptoms was not
secondary to a comorbid neurologic illness, their
onset in the context of cognitive deterioration,
psychosis, and negative neurologic work-up makes
these symptoms suspect for being part of prodromal
schizophrenia. We posit that our patient’s case is
likely representative of many others in that because
his initial presenting symptoms were non-specific,
they could have been attributed to other causes.
Misdiagnosis and subsequent mistreatment are lost
opportunities for early intervention, making the
recognition of prodromal symptomatology critical to
obtaining early access to care.
CONCLUSION
Ultimately, we feel that our patient represents a
case where both neurocognitive and neuro-motor
symptomatology manifested prior to the onset of
his eventual psychosis. This case fits the view of
schizophrenia being neurodevelopmental in nature.
Given the dearth of prospective studies, this patient’s
case serves to add to the volume of knowledge
identifying possible biomarkers for screening and
diagnosing premorbid schizophrenia.
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